Abstract
E-cadherin is a transmemberane protein which is responsible for adhesion of endothelial cells. The aim of our study was to assess existing evidence of associations between reduced expression of E-cadherin and prognosis of ovarian cancer with a discussion of potential approaches to exploiting any prognostic value for improved clinical management. We conducted a meta-analysis of 9 studies (n=915 patients) focusing on the correlation of reduced expression of E-cadherin with overall survival. Data were synthesized with random or fixed effect hazard ratios. The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for E-cadherin positivity, and methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI). Combined hazard ratios suggested that reduced expression of E-cadherin positivity was associated with poor overall survival (OS), HR=2.10, 95% CI:1.13-3.06. The overall survival of the E-cadherin negative group with ovarian cancer was significant poorer than the E-cadherin positive group. Upregulation of E-cadherin is an attractive therapeutic approach that could exert significant effects on clinical outcome of ovarian cancer.
Highlights
Ovarian cancer is the leading cause of death in female reproductive system diseases which threaten women’s health worldwide
The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for E-cadherin positivity, and methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI)
Combined hazard ratios suggested that reduced expression of E-cadherin positivity was associated with poor overall survival (OS), HR= 2.10, 95% CI:1.13-3.06
Summary
Ovarian cancer is the leading cause of death in female reproductive system diseases which threaten women’s health worldwide. While in early stage the patient merely complain pelvic uncomfortable and ignore them in crisis. Though we have revealed obvious development in surgical techniques and imaging method, we fail to make diagnosis in early stage and take intervention timely. Prognosis associated with ovarian cancer is poor, five-year survival for all stages is 47% and less than 30% for advanced stages (Carter and Downs Jr, 2011). FIGO stage and grade of differentiation are recognized as classical prognostic factors, but they are unsufficient to predict an individual patient’s prognosis. Identification and validation of prognostic factors can help to evaluate prognosis of patients and may contribute to ovarian cancer screening and treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
